RE:RE:RE:RE:RE:RE:RE:RE:ATMYeah patients living longer in oncology trials is terrible news.
Everyone has clearly stated their discontent and disapproval of the board thus far. I have also commented as much. The company has certainly not engendered itself to its shareholders, they have done a poor job with development and a worse job with communication. However, the results have been very strong and the board is stacked with beasts. Our advisors are also monsters so I'm still very happy that the people who actually have shares, will make an absolute fortune.
Or you could invest in Crisper and see how much unicorn semen they can sell before the bottom drops out.